
NEKTAR THERAPEUTICS
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Nektar Therapeutics is a biopharmaceutical company that develops drug candidates using its polymer chemistry-based platforms, focusing on immunology and inflammation treatments. It generates revenue both from its own pipeline and through licensing and collaboration agreements with other pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ROBIN HOWARD WPresident & CEO | Sell | $15K | 429at $35.85 | Nov 17, 2026 |
| Zalevsky JonathanChief R&D Officer | Sell | $7K | 192at $35.85 | Nov 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable NKTR activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.